Clinical Trial Update: Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of chemotherapy with osimertinib in metastatic EGFR-mutated non-small cell lung cancer (lung adenocarcinoma), …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: The University of Hong Kong | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: NOT_YET_RECRUITING